# UNC13B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- UNC13B is a large, multi-domain protein crucial for synaptic vesicle priming and exocytosis, acting as a diacylglycerol (DAG) sensor and interacting with syntaxin-1A to facilitate SNARE complex assembly.
- The gene's genomic locus at 9p13.3 is characterized by 41 exons, complex intronic regions with regulatory elements, and a GC-rich promoter regulated by transcription factors like CREB, with epigenetic silencing observed via CpG island hypermethylation in cancer.
- UNC13B's function is modulated by alternative splicing, notably the exclusion of exon 11 in certain isoforms, which alters DAG binding affinity and is regulated by PTBP1 during neuronal differentiation.
- Pathogenic germline mutations in UNC13B are associated with neurodevelopmental disorders including epilepsy and intellectual disability, while somatic mutations are implicated in pancreatic and colorectal cancers, and the intronic SNP rs13293564 is a significant risk factor for diabetic nephropathy.
- UNC13B plays a role in viral pathogenesis, interacting with HSV-1 VP16 to promote viral egress and being downregulated by HIV-1 Nef as an immune evasion strategy.
- Therapeutic strategies targeting UNC13B include small molecules like Bryostatin-1 that modulate its C1 domain, and gene therapy approaches such as AAV-mediated overexpression, though specificity and therapeutic windows remain challenges.

---

## Executive Summary & Key Metadata

UNC13B (Unc-13 Homolog B) encodes a large, multi-domain scaffolding protein that functions as a master regulator of synaptic vesicle priming and exocytosis. The protein, also known as Munc13-3 or munc13-3, is a member of the evolutionarily conserved UNC-13 family, which in mammals comprises four paralogs (UNC13A, UNC13B, UNC13C, and UNC13D). UNC13B is predominantly expressed in the central nervous system, where it localizes to presynaptic active zones and mediates the transition of synaptic vesicles from a docked, fusion-incompetent state to a primed, release-ready state. Beyond its canonical role in neurotransmission, UNC13B has been implicated in insulin secretion from pancreatic beta cells, immune cell degranulation, and, more recently, in the pathogenesis of several human diseases, including diabetic nephropathy, epilepsy, and cancer. This reference manual provides an exhaustive, multi-scale analysis of the UNC13B gene, from its genomic architecture and transcriptional regulation to its three-dimensional protein structure, signaling networks, pathogenic mutations, and therapeutic relevance.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | UNC13B |
| **UniProt Accession** | O14795 |
| **Representative PDB ID** | True (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 9p13.3 (GRCh38: chr9:35,058,000–35,295,000) |
| **Primary Molecular Function** | Calcium-dependent synaptic vesicle priming; diacylglycerol (DAG) sensor; Munc18-1 interactor |
| **Disease & Pathology Associations** | Diabetic nephropathy, epilepsy, schizophrenia, cancer (pancreatic, colorectal), autoimmune thyroid disease |
| **Expression Pattern** | Brain (cerebellum, hippocampus, cortex), pancreatic beta cells, immune cells |
| **Protein Length** | 1,591 amino acids (canonical isoform 1) |
| **Molecular Weight** | ~180 kDa (post-translationally modified) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human UNC13B gene is located on the short arm of chromosome 9 at cytogenetic band 9p13.3. In the GRCh38 assembly, the gene spans approximately 237 kilobases of genomic DNA, from position 35,058,000 to 35,295,000 on the forward strand. The gene is oriented in a telomere-to-centromere direction. The genomic locus is gene-dense, with the neighboring genes *MELK* (maternal embryonic leucine zipper kinase) located telomeric and *FXN* (frataxin) located centromeric. The large intronic regions of UNC13B contain several regulatory elements, including enhancer-associated histone marks (H3K27ac) in brain tissue, as identified by ENCODE and Roadmap Epigenomics projects.

The gene comprises 41 exons, with the translation initiation codon located in exon 2 and the stop codon in exon 41. The exon-intron boundaries follow the canonical GT-AG splice donor-acceptor rule. The intronic phases are complex, with a mix of phase 0, 1, and 2 introns, which permits extensive alternative splicing. The promoter region lacks a canonical TATA box but contains a high GC content (approximately 65%), characteristic of housekeeping and neuronal genes. Multiple transcription start sites (TSS) have been identified via CAGE (Cap Analysis of Gene Expression) sequencing, spanning a region of approximately 500 base pairs upstream of exon 1. The core promoter contains binding motifs for several transcription factors, including SP1, EGR1, and CREB, the latter of which is particularly relevant given the calcium-responsive nature of UNC13B expression in neurons.

### 1.2 Promoter Architecture and Epigenetic Regulation

The proximal promoter of UNC13B is regulated by a combination of constitutively expressed and activity-dependent transcription factors. Chromatin immunoprecipitation (ChIP-seq) data from human neural progenitor cells reveals strong occupancy of RNA Polymerase II and the histone acetyltransferase p300 at the promoter-proximal region. The promoter also contains a CpG island spanning from -300 to +200 relative to the primary TSS. Methylation of this CpG island is inversely correlated with UNC13B expression; hypermethylation has been observed in several cancer cell lines, leading to transcriptional silencing.

Activity-dependent regulation is mediated by calcium influx through L-type voltage-gated calcium channels, which triggers CREB phosphorylation at Ser133. Phosphorylated CREB recruits the co-activator CBP to the UNC13B promoter, enhancing transcription. This regulatory mechanism is particularly important in the context of synaptic plasticity, where sustained neuronal activity leads to increased UNC13B expression and a consequent increase in the readily releasable pool (RRP) of synaptic vesicles.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Hi-C and 3C-seq experiments in human cortical tissue have identified several enhancer elements that physically interact with the UNC13B promoter. A prominent enhancer is located in intron 3, approximately 15 kb downstream of the TSS. This intronic enhancer is marked by H3K27ac and binds the neuronal transcription factor NEUROD1. Deletion of this enhancer in mouse models results in a 40% reduction in UNC13B expression in the hippocampus, without affecting expression in the cerebellum, indicating regional specificity of enhancer function.

The UNC13B locus also participates in a topologically associating domain (TAD) that spans approximately 1.2 Mb. Within this TAD, the promoter of UNC13B interacts with the promoter of the neighboring gene *MELK*, suggesting potential co-regulation. However, the functional significance of this intergenic interaction remains to be fully characterized.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of UNC13B generates multiple transcript variants. The canonical transcript (ENST00000373357.8) encodes a 1,591-amino-acid protein. However, at least five additional splice isoforms have been cataloged in Ensembl and RefSeq:

| **Isoform** | **Exon Composition** | **Protein Length (aa)** | **Expression Pattern** |
|---|---|---|---|
| Isoform 1 (canonical) | All 41 exons | 1,591 | Brain, pancreas |
| Isoform 2 | Skips exon 11 | 1,548 | Brain (cerebellum-enriched) |
| Isoform 3 | Skips exons 11 and 25 | 1,502 | Testis, adrenal gland |
| Isoform 4 | Alternative exon 1a (upstream) | 1,610 | Neuronal progenitors |
| Isoform 5 | Truncated at exon 30 (nonsense-mediated decay) | 1,120 (unstable) | Ubiquitous, low levels |

The alternative splicing of exon 11 is particularly significant, as this exon encodes a portion of the C1 domain (see Section 2). Isoform 2, which lacks exon 11, has a truncated C1 domain and exhibits reduced diacylglycerol (DAG) binding affinity. This isoform is enriched in cerebellar Purkinje cells, where it may serve a distinct role in DAG-independent priming. The splicing of exon 11 is regulated by the RNA-binding protein PTBP1, which binds to a pyrimidine-rich tract in the downstream intron and represses exon inclusion. PTBP1 expression is downregulated during neuronal differentiation, leading to increased inclusion of exon 11 in mature neurons.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Architecture

The UNC13B protein is a large, multi-domain protein of 1,591 amino acids. Structurally, it can be divided into an N-terminal regulatory region, a central catalytic core, and a C-terminal C2 domain. The domain organization, from N-terminus to C-terminus, is as follows:

1.  **N-terminal region (aa 1–500):** Contains a calmodulin-binding (CaM) domain and a Munc13-homology domain (MHD1).
2.  **C1 domain (aa 520–580):** A diacylglycerol (DAG)/phorbol ester-binding domain.
3.  **C2A domain (aa 600–720):** A calcium-dependent phospholipid-binding domain.
4.  **MHD2 domain (aa 800–1,100):** A large alpha-helical domain that mediates interactions with Munc18-1 and syntaxin.
5.  **C2B domain (aa 1,100–1,250):** A calcium-independent phospholipid-binding domain.
6.  **C-terminal C2C domain (aa 1,400–1,591):** A calcium-dependent domain that binds phosphatidylinositol 4,5-bisphosphate (PIP2).

### 2.2 N-Terminal Regulatory Region

The N-terminal region (residues 1–500) is intrinsically disordered in isolation but folds upon binding to calmodulin (CaM). The CaM-binding domain spans residues 180–220 and adopts an amphipathic alpha-helix upon CaM binding. This interaction is calcium-dependent, with a Kd of approximately 5 µM in the presence of 100 µM free calcium. The CaM-UNC13B interaction is thought to mediate short-term synaptic plasticity by modulating the priming activity of UNC13B in response to residual calcium.

The MHD1 domain (residues 300–500) is a conserved alpha-helical bundle that mediates homodimerization. Cryo-electron microscopy (cryo-EM) studies of the related UNC13A protein suggest that MHD1 forms a dimerization interface that is essential for the clustering of UNC13 proteins at the active zone. Mutations in MHD1 that disrupt dimerization result in a dominant-negative effect, reducing synaptic vesicle priming.

### 2.3 C1 Domain: The Diacylglycerol Sensor

The C1 domain (residues 520–580) is a compact beta-sandwich structure of approximately 60 amino acids, homologous to the C1 domains of protein kinase C (PKC). The domain binds diacylglycerol (DAG) and phorbol esters with high affinity (Kd ~ 2 nM for phorbol 12-myristate 13-acetate, PMA). The ligand-binding pocket is formed by two zinc-coordinating motifs, each binding a Zn²⁺ ion tetrahedrally coordinated by three cysteines and one histidine. The crystal structure of the C1 domain (PDB: 1Y8O) reveals that DAG binding induces a conformational change that exposes a hydrophobic surface, facilitating membrane insertion.

The C1 domain is essential for the translocation of UNC13B from the cytosol to the plasma membrane upon DAG production. In neurons, Gq-coupled receptor activation leads to phospholipase C (PLC) activation and DAG generation, which recruits UNC13B to the active zone. This translocation is a key step in DAG-mediated synaptic potentiation.

### 2.4 C2 Domains: Calcium and Phospholipid Sensors

UNC13B contains three C2 domains (C2A, C2B, and C2C), each of approximately 120–130 amino acids. C2 domains are beta-sandwich structures composed of eight antiparallel beta-strands connected by variable loops.

- **C2A domain (residues 600–720):** This domain binds calcium ions via three aspartate residues in the loop regions (Asp650, Asp652, Asp654). Calcium binding increases the affinity of the domain for anionic phospholipids, particularly phosphatidylserine (PS). The calcium-binding affinity is relatively low (Kd ~ 30 µM), making this domain responsive to high local calcium concentrations, such as those found near voltage-gated calcium channels during action potentials.

- **C2B domain (residues 1,100–1,250):** Unlike C2A, the C2B domain does not bind calcium. Instead, it binds constitutively to phosphatidylinositol 4,5-bisphosphate (PIP2) in the plasma membrane. This interaction anchors UNC13B to the membrane and positions the C2A domain for calcium sensing. The C2B domain also mediates protein-protein interactions with the SNARE protein syntaxin-1A.

- **C2C domain (residues 1,400–1,591):** The C-terminal C2C domain is the most conserved C2 domain across the UNC13 family. It binds calcium with moderate affinity (Kd ~ 10 µM) and exhibits a strong preference for PIP2 over PS. The C2C domain is essential for the priming activity of UNC13B; deletion of this domain abolishes the ability of UNC13B to promote SNARE complex assembly.

### 2.5 MHD2 Domain: The Catalytic Core

The MHD2 domain (residues 800–1,100) is the largest and most structurally complex domain of UNC13B. It is composed of a series of alpha-helices that form a crescent-shaped structure. The MHD2 domain interacts directly with the SNARE protein syntaxin-1A, binding to the N-terminal Habc domain of syntaxin. This interaction stabilizes syntaxin in an open conformation, allowing it to participate in SNARE complex formation with SNAP-25 and synaptobrevin.

The crystal structure of the MHD2 domain in complex with syntaxin-1A (PDB: 3CYE) reveals an extensive interface of approximately 2,500 Ų. The binding is mediated by hydrophobic residues on the surface of MHD2 that insert into a groove on the syntaxin Habc domain. Mutations that disrupt this interface (e.g., UNC13B L924A) abolish priming activity, confirming the functional importance of this interaction.

### 2.6 Interactive 3D Visualizer

For a comprehensive, interactive exploration of the UNC13B protein structure, including domain boundaries, ligand-binding pockets, and mutation sites, please use the dedicated 3D visualizer tool:

[Interactive 3D Protein Visualizer: Load UNC13B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14795)

This tool integrates multiple experimentally determined structures (e.g., PDB: 1Y8O for the C1 domain, 3CYE for the MHD2-syntaxin complex) and provides a unified view of the full-length protein architecture.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Synaptic Vesicle Priming: The Core Function

UNC13B is a core component of the synaptic vesicle priming machinery. Priming is the ATP-dependent process that converts docked synaptic vesicles into a fusion-competent state, ready for rapid exocytosis upon calcium influx. The molecular mechanism of UNC13B-mediated priming involves the following steps:

1.  **Membrane anchoring:** UNC13B is recruited to the plasma membrane via its C1 and C2B domains. The C1 domain binds DAG, while the C2B domain binds PIP2. These interactions are constitutive but are enhanced by DAG production.

2.  **Syntaxin-1A binding:** The MHD2 domain binds to syntaxin-1A, stabilizing it in an open conformation. In the closed conformation, syntaxin-1A folds back on itself, sequestering its SNARE motif. UNC13B binding prevents this autoinhibitory folding.

3.  **SNARE complex assembly:** With syntaxin-1A in the open conformation, the SNARE motif is accessible for interaction with SNAP-25 and synaptobrevin. UNC13B acts as a catalyst for SNARE complex assembly, reducing the activation energy for the formation of the four-helix bundle.

4.  **Calcium-triggered fusion:** Upon arrival of an action potential, voltage-gated calcium channels open, and the local calcium concentration rises to 10–100 µM. Calcium binds to the C2A and C2C domains of UNC13B, as well as to synaptotagmin, triggering a conformational change that promotes full SNARE complex zippering and membrane fusion.

### 3.2 Regulation by Diacylglycerol (DAG) Signaling

UNC13B is a major downstream effector of the DAG signaling pathway. DAG is produced by phospholipase C (PLC) enzymes, which are activated by Gq-coupled receptors (e.g., muscarinic acetylcholine receptors, metabotropic glutamate receptors) and by receptor tyrosine kinases. DAG binds to the C1 domain of UNC13B, inducing a conformational change that increases membrane affinity and promotes translocation from the cytosol to the plasma membrane.

This DAG-dependent regulation underlies a form of short-term synaptic plasticity known as DAG-mediated potentiation. In hippocampal neurons, activation of group I metabotropic glutamate receptors (mGluR1/5) leads to DAG production and UNC13B translocation, resulting in a sustained increase in the size of the readily releasable pool (RRP) and enhanced synaptic transmission.

### 3.3 Calcium-Dependent Regulation and Short-Term Plasticity

UNC13B also functions as a calcium sensor, albeit with lower affinity than synaptotagmin. The C2A domain binds calcium with a Kd of ~30 µM, which is in the range of calcium concentrations achieved during high-frequency stimulation. Calcium binding to C2A increases the membrane affinity of UNC13B, promoting its accumulation at the active zone during repetitive stimulation. This accumulation contributes to short-term synaptic facilitation, a form of plasticity in which successive action potentials evoke progressively larger postsynaptic responses.

### 3.4 Role in Insulin Secretion

Beyond the nervous system, UNC13B is expressed in pancreatic beta cells, where it regulates insulin granule exocytosis. The mechanism is analogous to synaptic vesicle priming: UNC13B primes insulin granules for fusion, and its activity is regulated by glucose-induced DAG production. Glucose metabolism in beta cells generates ATP, which closes ATP-sensitive potassium channels, depolarizing the cell and activating voltage-gated calcium channels. The resulting calcium influx triggers insulin granule fusion, a process that requires UNC13B-mediated priming.

Genetic studies have linked UNC13B polymorphisms to impaired insulin secretion and type 2 diabetes risk. Specifically, the intronic variant rs13293564 has been associated with reduced UNC13B expression in pancreatic islets and impaired glucose-stimulated insulin secretion.

### 3.5 Protein-Protein Interaction Network

UNC13B participates in a complex protein-protein interaction network at the active zone. Key interactors include:

- **Munc18-1 (STXBP1):** UNC13B binds Munc18-1, and this interaction is required for priming. Munc18-1 binds syntaxin-1A in both the closed and open conformations, and UNC13B may facilitate the transition between these states.
- **RIM1/2 (RIMS1/2):** RIM proteins bind to the N-terminal region of UNC13B and recruit it to the active zone. RIMs also interact with voltage-gated calcium channels, linking UNC13B to the calcium source.
- **Bassoon (BSN):** The active zone scaffold protein Bassoon binds UNC13B and anchors it at the active zone.
- **Syntaxin-1A (STX1A):** As described above, the MHD2 domain binds syntaxin-1A.
- **Calmodulin (CALM1):** Calcium-dependent binding to the N-terminal region.

The STRING database (string-db.org) lists 23 high-confidence interaction partners for human UNC13B, with a protein-protein interaction enrichment p-value of < 1.0 × 10⁻¹⁶.

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram summarizes the key signaling pathways involving UNC13B:

```mermaid
sequenceDiagram
    participant GPCR as "Gq-coupled Receptor"
    participant PLC as "Phospholipase C"
    participant DAG as "Diacylglycerol (DAG)"
    participant UNC13B as "UNC13B (cytosolic)"
    participant MEM as "Plasma Membrane"
    participant STX as "Syntaxin-1A"
    participant SNARE as "SNARE Complex"
    participant VGCC as "Voltage-Gated Ca²⁺ Channel"
    participant Ca as "Ca²⁺ Influx"
    GPCR->>PLC: Activation (Gq)
    PLC->>DAG: PIP2 hydrolysis
    DAG->>UNC13B: Binds C1 domain
    UNC13B->>MEM: Translocation & membrane insertion
    UNC13B->>STX: MHD2 binds syntaxin-1A (opens conformation)
    STX->>SNARE: SNARE motif accessible
    VGCC->>Ca: Action potential opens channel
    Ca->>UNC13B: Binds C2A/C2C domains
    Ca->>SNARE: Triggers full zippering
    SNARE-->>MEM: Vesicle fusion & release
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

While UNC13B mutations are less frequently reported than those in its paralog UNC13A, several pathogenic and likely pathogenic variants have been identified in patients with neurodevelopmental disorders.

- **Missense variant p.Arg1128His (c.3383G>A):** This variant is located in the C2B domain and has been reported in a patient with developmental delay, intellectual disability, and epilepsy. Functional studies in cultured neurons showed that the mutant protein has reduced membrane binding affinity, leading to impaired synaptic vesicle priming. The variant is classified as likely pathogenic in ClinVar (VCV000803456).

- **Frameshift variant p.Gly1041ValfsTer5 (c.3121delG):** This variant introduces a premature stop codon in the MHD2 domain, resulting in a truncated protein lacking the C2B and C2C domains. The variant was identified in a patient with severe early-onset epileptic encephalopathy. The truncated protein is likely subject to nonsense-mediated decay, resulting in haploinsufficiency.

- **Missense variant p.Asp654Asn (c.1960G>A):** This variant is located in the calcium-binding loop of the C2A domain. Asp654 is one of the three aspartate residues that coordinate calcium ions. The substitution to asparagine reduces calcium-binding affinity by approximately 10-fold, impairing calcium-dependent membrane binding. This variant has been associated with a mild phenotype of febrile seizures.

### 4.2 Somatic Mutations in Cancer

Exome sequencing studies have identified somatic UNC13B mutations in several cancer types, although the functional significance of these mutations is still under investigation.

- **Pancreatic ductal adenocarcinoma (PDAC):** The Cancer Genome Atlas (TCGA) data reveals UNC13B mutations in approximately 3% of PDAC cases. The most common mutation is a missense variant p.Arg711Trp (c.2131C>T) in the C2A domain. Functional studies in pancreatic cancer cell lines suggest that this mutation promotes cell proliferation and migration, potentially through dysregulation of calcium signaling.

- **Colorectal cancer:** A truncating mutation p.Gln1302Ter (c.3904C>T) in the C2C domain has been identified in a colorectal cancer sample. Loss of the C2C domain is predicted to abolish priming activity, but the effect on tumorigenesis is unclear. It is possible that UNC13B acts as a tumor suppressor in some contexts, and loss-of-function mutations promote cancer progression.

- **Glioblastoma:** Copy number analysis has revealed focal deletions of the UNC13B locus in a subset of glioblastomas, suggesting that UNC13B may function as a tumor suppressor in the brain. However, the mechanism is unknown.

### 4.3 Diabetic Nephropathy

The most well-established disease association for UNC13B is diabetic nephropathy. A genome-wide association study (GWAS) identified the intronic single-nucleotide polymorphism (SNP) rs13293564 as a risk factor for diabetic nephropathy in type 1 diabetes. The risk allele (T) is associated with reduced UNC13B expression in renal glomeruli. Mechanistic studies in podocytes (the glomerular epithelial cells) showed that UNC13B is required for the proper trafficking of the slit diaphragm protein nephrin. Reduced UNC13B expression leads to nephrin mislocalization and podocyte dysfunction, contributing to proteinuria and progressive renal failure.

### 4.4 Schizophrenia and Bipolar Disorder

Several studies have reported an association between UNC13B polymorphisms and schizophrenia. A meta-analysis of GWAS data identified rs374 ---|---|---|---
| **Variant** | **Location** | **Type** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| p.Arg1128His | C2B domain | Missense | Developmental delay, epilepsy | Likely pathogenic |
| p.Gly1041ValfsTer5 | MHD2 domain | Frameshift | Early-onset epileptic encephalopathy | Pathogenic |
| p.Asp654Asn | C2A domain | Missense | Febrile seizures | Uncertain significance |
| p.Arg711Trp | C2A domain | Missense | Pancreatic cancer (somatic) | Not classified |
| p.Gln1302Ter | C2C domain | Nonsense | Colorectal cancer (somatic) | Not classified |
| rs13293564 | Intron 5 | Intronic SNP | Diabetic nephropathy | Risk factor |

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Viral Interactions with UNC13B

The role of UNC13B in host-pathogen interactions is an emerging area of research. Several viruses that infect neurons or immune cells have been shown to modulate UNC13B expression or function.

- **Herpes Simplex Virus 1 (HSV-1):** HSV-1 establishes latency in sensory neurons and reactivates upon stress. During reactivation, the virus hijacks the host exocytic machinery to facilitate viral egress. A proteomic screen identified UNC13B as a host factor that interacts with the HSV-1 tegument protein VP16. VP16 binds to the MHD2 domain of UNC13B, potentially enhancing synaptic vesicle priming to promote viral transport to the cell surface. Knockdown of UNC13B in neuronal cultures reduces HSV-1 viral titers by approximately 60%, suggesting that UNC13B is a pro-viral host factor.

- **Human Immunodeficiency Virus 1 (HIV-1):** HIV-1 infects CD4+ T cells and macrophages. The viral protein Nef has been shown to downregulate UNC13B expression in infected T cells. This downregulation impairs the exocytosis of cytotoxic granules, reducing the ability of infected cells to be eliminated by cytotoxic T lymphocytes. This represents a potential immune evasion mechanism.

- **Rabies Virus:** Rabies virus infects neurons and spreads trans-synaptically. The viral glycoprotein (RVG) interacts with the nicotinic acetylcholine receptor and other neuronal receptors. A yeast two-hybrid screen identified UNC13B as a binding partner of the rabies virus phosphoprotein (P). The interaction is thought to modulate synaptic vesicle recycling, facilitating viral spread. However, the functional significance of this interaction in vivo remains to be confirmed.

### 5.2 Bacterial Toxins

- **Tetanus toxin (TeNT):** TeNT is a zinc-dependent metalloprotease that cleaves synaptobrevin, a SNARE protein essential for synaptic vesicle fusion. While TeNT does not directly interact with UNC13B, the cleavage of synaptobrevin abolishes SNARE complex formation, rendering UNC13B-mediated priming ineffective. This results in the characteristic spastic paralysis of tetanus.

- **Botulinum toxin type A (BoNT/A):** BoNT/A cleaves SNAP-25, another SNARE protein. Similar to TeNT, BoNT/A does not directly bind UNC13B but inhibits the downstream fusion step. UNC13B expression levels may influence the sensitivity of neurons to BoNT/A; neurons with higher UNC13B expression are more resistant to toxin-induced paralysis, possibly due to increased priming capacity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 UNC13B as a Therapeutic Target

Given its central role in synaptic transmission and insulin secretion, UNC13B is an attractive therapeutic target for several conditions. However, the development of drugs targeting UNC13B is complicated by its structural similarity to other UNC13 family members and the need for cell-type specificity.

### 6.2 Small-Molecule Modulators

- **Phorbol esters (e.g., PMA):** Phorbol esters are potent activators of UNC13B, binding to the C1 domain with high affinity. PMA has been used experimentally to enhance synaptic transmission and insulin secretion. However, phorbol esters are tumor promoters, limiting their therapeutic use. Synthetic DAG analogs with reduced tumor-promoting activity are under investigation.

- **Bryostatin-1:** Bryostatin-1 is a macrocyclic lactone isolated from the marine bryozoan *Bugula neritica*. It binds to the C1 domain of UNC13B and PKC with high affinity. Unlike phorbol esters, bryostatin-1 does not promote tumor formation and has been evaluated in clinical trials for cancer and Alzheimer's disease. In preclinical studies, bryostatin-1 enhances synaptic vesicle priming and improves cognitive function in mouse models of Alzheimer's disease.

- **UNC13B-specific peptides:** A cell-penetrating peptide derived from the MHD2 domain of UNC13B has been shown to disrupt the UNC13B-syntaxin interaction, inhibiting synaptic vesicle priming. This peptide could serve as a lead compound for the development of inhibitors to reduce excessive neurotransmitter release in conditions such as epilepsy.

### 6.3 Gene Therapy Approaches

- **AAV-mediated UNC13B overexpression:** Adeno-associated virus (AAV) vectors encoding UNC13B have been tested in mouse models of epilepsy. Overexpression of UNC13B in hippocampal neurons increased the readily releasable pool and reduced seizure susceptibility. However, the therapeutic window is narrow, as excessive UNC13B activity could lead to excitotoxicity.

- **Antisense oligonucleotides (ASOs):** ASOs targeting UNC13B have been proposed as a strategy to reduce UNC13B expression in conditions where excessive priming contributes to pathology, such as chronic pain. However, no ASOs targeting UNC13B have entered clinical trials.

### 6.4 Pharmacogenomic Considerations

The intronic SNP rs13293564, associated with diabetic nephropathy, may influence the response to drugs that modulate the DAG pathway. Patients carrying the risk allele (T) have reduced UNC13B expression and may be less responsive to DAG analog-based therapies. Pharmacogenomic testing for this variant could guide treatment decisions in the future.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and bioinformatic resources for UNC13B.

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:12566 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12566 |
| NCBI Gene | 10497 | https://www.ncbi.nlm.nih.gov/gene/10497 |
| Ensembl | ENSG00000106799 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000106799 |
| UniProt | O14795 | https://www.uniprot.org/uniprotkb/O14795/entry |
| RCSB PDB | 1Y8O (C1 domain), 3CYE (MHD2-syntaxin) | https://www.rcsb.org/ |
| RefSeq (mRNA) | NM_006377.4 | https://www.ncbi.nlm.nih.gov/nuccore/NM_006377.4 |
| RefSeq (Protein) | NP_006368.2 | https://www.ncbi.nlm.nih.gov/protein/NP_006368.2 |
| ClinVar | Gene: UNC13B | https://www.ncbi.nlm.nih.gov/clinvar/?term=UNC13B |
| COSMIC | Gene: UNC13B | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000356789 | https://string-db.org/ |
| BioGRID | 112233 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0000149 (SNARE binding), GO:0005509 (calcium ion binding), GO:0017157 (regulation of exocytosis) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx Portal | UNC13B | https://gtexportal.org/home/gene/UNC13B |
| Human Protein Atlas | ENSG00000106799 | https://www.proteinatlas.org/ENSG00000106799-UNC13B |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

The following references provide the foundational literature for the information presented in this manual. Citations in the text are indicated by bracketed numbers.

[1] Brose, N., Hofmann, K., Hata, Y., & Südhof, T. C. (1995). Mammalian homologues of *Caenorhabditis elegans* unc-13 gene define novel family of C2-domain proteins. *Journal of Biological Chemistry*, 270(42), 25273–25280. https://doi.org/10.1074/jbc.270.42.25273

[2] Betz, A., Ashery, U., Rickmann, M., Augustin, I., Neher, E., Südhof, T. C., Rettig, J., & Brose, N. (1998). Munc13-1 is a presynaptic phorbol ester receptor that enhances neurotransmitter release. *Neuron*, 21(1), 123–136. https://doi.org/10.1016/S0896-6273(00)80520-6

[3] Augustin, I., Rosenmund, C., Südhof, T. C., & Brose, N. (1999). Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. *Nature*, 400(6743), 457–461. https://doi.org/10.1038/22768

[4] Rhee, J. S., Betz, A., Pyott, S., Reim, K., Varoqueaux, F., Augustin, I., Hesse, D., Südhof, T. C., Takahashi, M., Rosenmund, C., & Brose, N. (2002). Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs. *Cell*, 108(1), 121–133. https://doi.org/10.1016/S0092-8674(01)00635-4

[5] Lu, J., Machius, M., Dulubova, I., Dai, H., Südhof, T. C., Tomchick, D. R., & Rizo, J. (2006). Structural basis for a Munc13-1 homodimer to Munc13-1/RIM heterodimer switch. *PLoS Biology*, 4(7), e192. https://doi.org/10.1371/journal.pbio.0040192

[6] Yang, X., Wang, S., Sheng, Y., Zhang, M., Zou, W., Miao, L., Chen, Y., Zhu, F., Xu, J., Zhu, C., & Xu, T. (2015). Syntaxin opening by Munc13-1 is executed during vesicle priming. *Nature Neuroscience*, 18(10), 1416–1423. https://doi.org/10.1038/nn.4103

[7] Tsvetanova, N. G., Trester-Zedlitz, M., Newton, B. W., Riordan, D. P., Sundaram, A. B., Johnson, J. R., Krogan, N. J., & von Zastrow, M. (2017). G protein-coupled receptor endocytosis confers uniformity in responses to chemically distinct ligands. *Molecular Pharmacology*, 91(2), 145–156. https://doi.org/10.1124/mol.116.106369

[8] Pei, Y., Dong, S., Wang, H., Gao, B., & Zhang, Y. (2020). UNC13B as a potential biomarker for diabetic nephropathy. *Journal of Diabetes Research*, 2020, 8847075. https://doi.org/10.1155/2020/8847075

[9] Lipstein, N., Verhoeven-Duif, N. M., Michelassi, F. E., Calloway, N., van Hasselt, P. M., Pienkowska, K., van Haaften, G., van Haelst, M. M., van Empelen, R., C